Antibody–drug conjugates in the treatment of lymphoid neoplasms

Summary Antibody-drug conjugates (ADCs) are a new class of monoclonal antibodies with the characteritic to specifically target tumor cells and to deliver a cytotoxic drug directly to the target cell thereby minimising side effects and improving the therapeutic index. In recent years, many new ADCs h...

Full description

Saved in:

Bibliographic Details
Published in:	Memo - Magazine of European medical oncology Vol. 17; no. 2; pp. 135 - 139
Main Authors:	Neumeister, Peter, Prochazka, Katharina Theresa
Format:	Journal Article
Language:	English
Published:	Vienna Springer Vienna 01-05-2024
Subjects:	Medicine Medicine & Public Health Oncology Short Review Loncastuximab tesirine Diffuse large B‑cell lymphoma Brentuximab vedotin Inotuzumab ozogamicin Polatuzumab vedotin Hodgkin’s lymphoma
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Summary Antibody-drug conjugates (ADCs) are a new class of monoclonal antibodies with the characteritic to specifically target tumor cells and to deliver a cytotoxic drug directly to the target cell thereby minimising side effects and improving the therapeutic index. In recent years, many new ADCs have been approved and are established therapeutic tools in lymphoma treatment.
ISSN:	1865-5041 1865-5076
DOI:	10.1007/s12254-024-00965-x